We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Test Predicts Risk of Severe Liver Disease

By LabMedica International staff writers
Posted on 01 Oct 2025

Severe liver diseases such as cirrhosis and liver cancer are becoming increasingly common and often carry a poor prognosis when detected late. More...

Current screening tools are limited in their ability to identify people at risk early, leaving many patients undiagnosed until the disease has progressed. Researchers have now demonstrated that a simple blood analysis can predict the risk of developing severe liver disease up to 10 years in advance, offering a pathway for earlier detection.

A team of researchers at Karolinska Institutet (Stockholm, Sweden), along with Finnish collaborators, has developed a model called CORE to estimate risk using advanced statistical methods. The model is based on five factors: age, sex, and levels of three common liver enzymes (AST, ALT, and GGT), which are routinely measured during standard health checks. To facilitate use in primary care, a web-based calculator has already been launched, enabling doctors and nurses to apply the tool easily.

The study analyzed data from more than 480,000 people in Stockholm who underwent health checks between 1985 and 1996. Participants were followed for up to 30 years, during which about 1.5 percent developed severe liver disease, including cirrhosis, liver cancer, or the need for a liver transplant. The findings, published in The BMJ, shows that the CORE model can accurately identify individuals most likely to develop severe liver disease.

The results demonstrated that the CORE model correctly differentiated between those who developed disease and those who did not in 88 percent of cases, outperforming the widely used FIB-4 method. Importantly, it proved accurate not only in Swedish participants but also when tested on populations in Finland and the UK. Researchers note, however, that further validation is needed in groups at especially high risk, such as individuals with obesity or type 2 diabetes.

The study highlights the potential for CORE to be integrated into primary care settings where most patients first seek medical attention. Early identification could enable timely interventions, including drug treatments that are becoming available for people at high risk of cirrhosis or liver cancer. Future steps include embedding the model into medical record systems and further evaluating its performance in diverse patient groups.

“These are diseases that are growing increasingly common and that have a poor prognosis if detected late,” said Rickard Strandberg, one of the developers of the new test. “Our method can predict the risk of severe liver disease within 10 years and is based on three simple routine blood tests.”

Related Links:
Karolinska Institutet


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.